Effects of Aldosterone and Angiotensin II Receptor Blockade on Cardiac Angiotensinogen and Angiotensin-Converting Enzyme 2 Expression in Dahl Salt-Sensitive Hypertensive Rats

American Journal of Hypertension

Volumn 20, Issue 10, 2007, Pages 1119-1124

  Takeda, Yoshiyu ^a   Zhu, Aoshuang ^a   Yoneda, Takashi ^a   Usukura, Mikiya ^a   Takata, Hiroyuki ^a   Yamagishi, Masakazu ^a  

^a Graduate School of Medical Science   (Japan)

Author keywords

Aldosterone antagonist; angiotensin antagonist; hypertension; hypertrophy; sodium

Indexed keywords

ALDOSTERONE RECEPTOR; ANGIOTENSIN RECEPTOR; ANGIOTENSINOGEN; CANDESARTAN; COLLAGEN TYPE 3; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE 2; EPLERENONE; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DISEASE MODEL; DRUG EFFECT; DRUG MECHANISM; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; HYPERTENSION; MALE; NONHUMAN; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SALT INTAKE;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSINOGEN; ANIMALS; BENZIMIDAZOLES; CARDIOMEGALY; ENDOTHELIUM, VASCULAR; FIBROSIS; HYPERTENSION; MALE; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, INBRED DAHL; RECEPTOR, ANGIOTENSIN, TYPE 1; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SPIRONOLACTONE; TETRAZOLES;

EID: 34548822986     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2007.05.008     Document Type: Article

References (29)

1. Takeda Y. Genetic alterations in patients with primary aldosteronism. Hypertens Res 24 (2001) 469-474
2. Pitt B., Remme W.J., Zannad F., Neaton J., Maerinez F., Roniker B., Bittman R., Hurley S., Kleiman J., and Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
3. Endemann D.H., Touyz R.M., Iglarz M., Savoia C., and Schiffrin E.L. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 43 (2004) 1-6
4. Ingert C., Grima M., Cowuard C., Barthelmebs M., and Imbs J.-L. Effects of dietary salt changes on renal renin-angiotensin system in rats. Am J Physiol Renal Physiol 283 (2002) F995-F1002
5. Kobori H., Nishiyama A., Abe Y., and Navar L.G. Enhancement of intrarenal angiotensinogen in Dahl salt-sensitive rats on high salt diet. Hypertension 41 (2003) 592-597
6. Bartel S., Hoch B., Vetter D., and Krause E.-G. Expression of human angiotensinogen-renin in rat. Hypertension 39 (2002) 219-223
7. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., Oliveira-dos-Santos A.J., da Costa J., Zhang L., Pei Y., Scholey J., Ferrario C.M., Manoukian A.S., Chappell M.C., Backx P.H., Yagil Y., and Penninger J.M. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002) 822-828
8. Takeda Y., Yoneda T., Demura M., Miyamori I., and Mabuchi H. Cardiac aldosterone production in genetically hypertensive rats. Hypertension 36 (2000) 495-500
9. Takeda Y., Miyamori I., Wu P., Yoneda T., Furukawa K., and Takeda R. Effects of an endothelin receptor antagonist in rats with cyclosporine-induced hypertension. Hypertension 26 (1995) 932-936
10. Naito Y., Tsujino T., Fujioka Y., Ohyanagi M., and Iwasaki T. Augmented diurnal variations of the cardiac rennin-angiotensin system in hypertensive rats. Hypertension 40 (2002) 827-833
11. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., and Cooper M.E. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 41 (2003) 392-397
12. Takeda Y., Yoneda T., Demura M., Usukura M., and Mabuchi H. Calcineurin inhibition attenuates mineralocortiocid-induced cardiac hypertrophy. Circulation 105 (2002) 677-679
13. Nagase M., Shibata S., Yoshida S., Nagase T., Gotoda T., and Fujita T. Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker. Hypertension 47 (2006) 1084-1093
14. Nagata K., Obata K., Xu J., Ichihara S., Noda A., Kimata H., Kato T., Izawa H., Murohata T., and Yokota M. Mineralocorticoid receptor antagonism attenuates cardiac hypertrophy and failure in low-aldosterone hypertensive rats. Hypertension 47 (2006) 656-664
15. Flack J.M., Oparil S., Pratt H., Roniker B., Garthwaite S., Kleiman J.H., Yang Y., Krause S.L., Workman D., and Saunders E. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol 41 (2003) 1148-1155
16. Pitt B., Reichek N., Willenbrock R., Zannad F., Phillips R.A., Roniker B., Kleiman J., Krause S., Burns D., and Williams G.H. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy. Circulation 108 (2003) 1831-1838
17. Griffin K.A., Abu-Amarah I., Picken M., and Bidani A.K. Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent. Hypertension 41 (2003) 201-206
18. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 37 (2001) 677-688
19. Mazzolai L., Nussberger J., Aubert J.F., Brunner D.B., Gabbiani G., Brunner H.R., and Pedrazzini T. Blood pressure-independent cardiac hypertrophy induced by locally activated renin-angiotensin system. Hypertension 31 (1998) 1324-1330
20. Harada E., Yoshimura M., Yasue H., Nakagawa O., Nakagawa M., Harada M., Mizuno Y., Nakayama M., Shimasaki Y., Ito T., Nakamura S., Kuwahara K., Saito Y., Nakao K., Ogawa H., Robinson A.D., and Weber K.T. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation 104 (2001) 137-139
21. Sun Y., Zhang J., Lu L., Bedigian M.P., Robinson A.D., and Weber K.T. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med 143 (2004) 41-51
22. Resende M.M., and Mikk J.G. Effect of high salt intake on local renin-angiotensin system and ventricular dysfunction following myocardial infarction in rats. Clin Exp Phamacol Physiol 34 (2007) 274-279
23. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., Tatara Y., Shiota A., Sugano S., Takeda S., Rakugi H., and Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 47 (2006) 718-726
24. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., Diz D.I., and Gallagher P.E. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111 (2005) 2605-2610
25. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., and Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 43 (2004) 1-7
26. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M., Ferrario C.M., and Raizada M.K. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 90 (2005) 783-790
27. Kobayashi N., Yoshida K., Nakano S., Ohno T., Honda T., Tsubokou Y., and Matsuoka H. Cardioprotective mechanisms of eplerenone on cardiac performance and remodeling in failing rat hearts. Hypertension 47 (2006) 671-679
28. Quaschning T., Ruschitzka F., Shaw S., and Luscher T.F. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 37 (2001) 801-805
29. Blasi E.R., Rocha R., Rudolph A.E., Blomme E.A., Polly M.L., and McMahon E.G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63 (2003) 1791-1800